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doi:10.1Objective:Cefazolin (1–2 g bolus at induction possibly repeated after cardiopulmonary bypass) remains the stan-
dard for antibiotic prophylaxis in cardiac surgery. Data indicate, however, that it is underdosed with this dosing
schedule. A prospective, randomized study comparing intermittent versus loading dose plus continuous infusion
for the same total dose of cefazolin was performed to assess which modality is pharmacokinetically and pharma-
codynamically advantageous.
Methods: Patients received 2 g cefazolin as a starting dose and then were divided into an intermittent group (re-
ceiving another 1 g at 3, 9, and 15 hours after the first dose) and a continuous group (continuous infusion started
after the first dose, providing 1 g every 6 hours for 18 hours). Cefazolin levels were measured in blood and atria.
Results: Mean total and calculated free trough concentrations in blood varied greatly among patients in the in-
termittent group and were lower than those in the continuous group (P<.05 at 15, 18 and 24 hours). For 9 of 10
(90%) patients in the continuous infusion group, the targeted pharmacokinetic and pharmacodynamic goal (time
above minimal inhibitory concentration>90%) was achieved, whereas the goal was met for only 3 of 10 (30%)
in the intermittent group (P<.05). The mean atrial tissue concentration was also higher with continuous infusion
(P< .05).
Conclusions: Administration of cefazolin as bolus plus continuous infusion has pharmacokinetic and pharmaco-
dynamic advantages relative to intermittent administration. It provides more stable serum levels, lower interpa-
tient variability, and higher myocardial tissue penetration. (J Thorac Cardiovasc Surg 2010;140:471-5)Surgical site infections (SSIs) complicate elective cardiac
surgery in 3% to 10% of cases.1-4 Cefazolin, because of
its spectrum of activity, safety, and low cost, is still the
standard drug of choice for antibiotic prophylaxis in
elective cardiac surgery, unless the patient is allergic to
b-lactams or there is a high (usually>20%) prevalence of
methicillin-resistant Staphylococcus aureus infection.5 It is
well known that the success of antibiotic prophylaxis de-
pends not only on selection of the appropriate antimicrobial
drug but also on its administration so that peak blood con-
centrations are achieved before skin incision and adequate
levels are maintained during the whole surgical procedure
and early postoperative period.5 Time-dependent antibacte-
rial agents such as cefazolin should reach and maintain con-
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M(MIC) for at least 40% to 50%6–or even better, for more
than 90%6,7–of the dosing interval. In cardiac surgery,
cefazolin is usually administered intermittently as a 1- to
2-g intravenous bolus before induction of anesthesia,
possibly repeated after onset of cardiopulmonary bypass
(CPB) or at wound closure.5 Drug plasma levels may be pro-
foundly altered during CPB, however, mainly as a result of
increased volume of distribution, resulting in underdosing.8
As shown by Caffarelli and colleagues,9 1 g cefazolin ad-
ministered at induction and repeated at wound closure pro-
vides plasma levels lower than 8 mg/mL (sensitivity
threshold for cefazolin10) in 50% of patients undergoing
CPB for longer than 120 minutes. Similarly, in patients un-
dergoing coronary artery bypass grafting, plasma levels of
cefazolin after administration of 1 g at induction and 1 g im-
mediately after onset of CPB fluctuated considerably during
the intraoperative period, falling below the 90% MIC for
Enterobacter species and Escherichia coli in most patients.1
These data indicate that the drug is frequently underdosed,
with the risk of both failure to prevent SSIs and a possible
increase in the spread of resistance.11 To compensate for ce-
fazolin’s short elimination half-life,12 we hypothesized that
it could be administered as a loading bolus followed by con-
tinuous infusion. This study was therefore performed to as-
sess which administration schedule (intermittent vs loading
dose plus continuous infusion) of the same amount ofrdiovascular Surgery c Volume 140, Number 2 471
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
MIC ¼ minimal inhibitory concentration
SSI ¼ surgical site infections
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Mcefazolin would yield a better pharmacokinetic and pharma-
codynamic profile as antibiotic prophylaxis in patients un-
dergoing cardiac surgery with CPB.MATERIALS AND METHODS
This prospective, randomized study was performed at a university-
affiliated hospital. The study was approved by the hospital ethics committee,
and patients gave informed consent to participate in the study. Enrolled
patients were divided into groups according to the modality of cefazolin ad-
ministration, intermittent or continuous. Exclusion criteria were as follows:
age younger than 18 years, pregnancy, suspected or confirmed intolerance
to cephalosporins, severe renal failure (creatinine clearance<40 mL/min,
calculated according to Cockcroft and Gault formula13), liver failure (serum
bilirubin concentration >2 mg/dL), neutropenia (neutrophil count
<500 cells/mm3), and diabetes (a specific risk factor for development of
SSIs, independent of type of surgery or schedule of prophylaxis administra-
tion). Patients with preexisting infections or history of antibiotic therapy
during the last 72 hours before surgery were excluded as well.
Patients in both groups were preoperatively scored according to the
EuroSCORE14 to predict operative mortality. All received the same type
of anesthesia and intraoperative management. In particular, fluid balance
was strictly monitored, with crystalloids and colloids used as fluid replace-
ment in a 3:1 ratio. After surgery, all patients were admitted to the cardio-
thoracic surgical intensive care unit, where they received the same
postoperative care. Fluids were infused to maintain a urinary output of at
least 1.5 mL/(kg $ h). The type of surgery, duration of surgery, and duration
of mechanical ventilation were recorded. The presence of SSIs was moni-
tored for 30 days after surgery. Bacteriologic examinations were performed
when SSI was suspected.
Patients in both the intermittent and continuous infusion groups received
(through a dedicated peripheral venous line) a 2-g dose of cefazolin as
a starting dose 30 minutes before skin incision. In the intermittent group, ad-
ditional 1-g doses of cefazolin were administered at the end of CPB (second
dose) and at 9 and 15 hours after the second dose. In the continuous infusion
group, a continuous infusion of 3 g cefazolin was started immediately after
the loading dose at a rate of 1 g every 6 hours (Figure 1). Patients in both
groups received a total of 5 g of cefazolin as prophylaxis.
To assay cefazolin serum levels, blood samples (3 mL) were collected
through an intra-arterial catheter placed contralaterally to the infusion site.
In both groups, blood samples were taken just before the loading dose infu-
sion, after completion of loading dose (0.5 hours, peak concentration), and
then at each trough and peak time for the intermittent group or at the corre-
sponding times for the continuous infusion group for 24 hours (Figure 1).
The samples were centrifuged and frozen at80C. To determine cefazolin
myocardial tissue penetration, samples of right atrial auricula were also taken
from some patients at the end of CPB. Cefazolin concentrations in serum and
myocardial tissue were determined in triplicate by a validated large-plate
agar diffusion technique, with a lower limit of sensitivity of 0.125 mg/L,15
according to Good Laboratory Practice standards. The correlation coefficient
was not less than 0.99. For all cefazolin samples, intra-assay precision ranged
from 1.5% to 6.8%. Pharmacokinetic analysis of cefazolin concentrations in
serum was performed with a computerized program (Syphar, version 4.0;
SIMED, Creteil-Cedex, France). The time when free serum concentrations
were greater than the MIC (considering 80% protein binding12) and the areas472 The Journal of Thoracic and Cardiovascular Surgunder the concentration curve relative to MIC were calculated for each pa-
tient for the pharmacokinetic and pharmacodynamic analysis.
Data are reported as mean SD if not otherwise indicated. Demographic
data were analyzed with 2-tailed Student t test. One-way analysis of vari-
ance and Duncan post hoc test were used for pharmacokinetic analysis.RESULTS
Ten patients in each group were enrolled in and completed
the study, and there were no differences between groups in
demographic characteristics (Table 1). No patients had ma-
jor intraoperative complications or adverse reactions to cefa-
zolin. No patients underwent renal replacement therapy. At
30 days after surgery, no patients had acquired a SSI.
The serum concentration time courses of individual pa-
tients in the intermittent and continuous infusion groups
are depicted in Figure 2 (A and B, respectively). Trough se-
rum concentrations are reported in Table 2. Peak concentra-
tions after the starting dose were similar (184.2 19.8 mg/L
vs 165.4  29.9 mg/L for intermittent and continuous infu-
sion groups, respectively, difference not significant), as were
the areas under the curve for 0 to 24 hours (1550.9  310.2
vs 1699.7  204.5, difference not significant). In the inter-
mittent group, there was wide intragroup fluctuation in total
trough cefazolin concentration, with values in individual pa-
tients as low as 5.2 mg/L at 14.5 hours, 8.7 mg/L at 21 hours,
and 0 mg/L at 24 hours (Figure 2 and Table 2). In contrast,
the average intrapatient total concentration was stable (be-
tween 51.3 2 mg/L and 57.6 13 mg/L) during the entire
24-hour study period in the continuous infusion group, with
the lowest value being 27.5 mg/L. The differences in serum
levels reflect the significant difference in mean total cefazo-
lin concentrations in myocardial tissue between the intermit-
tent and continuous infusion groups (3.28  0.1 mg/L in the
intermittent group vs 6.9 1.1 mg/L in the continuous infu-
sion group, n ¼ 6 each group, P< .05). Looking at the cal-
culated (considering 80% protein binding12) concentrations
of the free drug, all mean trough values were lower than
8 mg/L in the intermittent group, and corresponding values
were always greater than 10 mg/L in the continuous infusion
group. Fifty percent of patients in the intermittent group had
serum levels lower than 8 mg/L (the susceptibility break-
point for E coli) for the entire study period, and 25% had
levels lower than 4 mg/L (the susceptibility breakpoint for
S aureus). The pharmacokinetic and pharmacodynamic
analysis of free concentrations (Figure 3) showed that in
the intermittent group only 3 of 10 patients (30%) had con-
centrations above the MIC threshold of 8 mg/L more than
90% of the time. In contrast, 90% of patients in the contin-
uous infusion group (9/10) had values greater than the MIC
more than 90% of the time (P< .01).DISCUSSION
We found that a better pharmacokinetic and pharmacody-
namic profile emerged from administering cefazolin asery c August 2010
CPBInduction                                                 End of surgery 
2 g cefazolin                      1 g cefazolin          1 g cefazolin        1 g cefazolin
2 g cefazolin         +          3 g cefazolin continuous infusion (1 g / 6 h) 
Continuous infusion 
Intermittent infusion 
3                              9                           15                      18                           24          hours
= Myocardial samples          = Serum samples 
FIGURE 1. Experimental design time course. CPB, Cardiopulmonary bypass.
Adembri et al Perioperative Managementa bolus followed by continuous infusion rather than accord-
ing to the standard administration schedule as prophylaxis in
elective cardiac surgery. Continuous infusion provided se-
rum levels more consistently above the target (greater than
MIC for>90% of the time) for the most likely susceptible
pathogens in all patients, and the duration of effective cefa-
zolin serum level was extended without any increase in the
total amount of drug given. Finally, myocardial tissue pene-
tration of the drug was enhanced with continuous adminis-
tration relative to intermittent administration.
Guidelines for thoracic and cardiovascular surgery still
recommend cefazolin as first-line prophylaxis, to be admin-
istered intermittently as boluses of 1 to 2 g at induction and
possibly repeated at the end of CPB or at wound closure.5 Be-
cause of its short half-life (<2 hours) and because of pharma-
cokinetic alterations caused by CPB that result in 30% to
40% decreases in plasma levels of hydrophilic drugs, stan-
dard dosages at fixed intervals are often suboptimal, even
in the intraoperative period, and expose the patient to a higherTABLE 1. Clinical and demographic characteristics of patients
receiving continuous or intermittent cefazolin infusion
Intermittent Continuous
Sex (male/female) 8:2 7:3
Age (y, mean  SD) 67.9  9.6 61.9  9.5
Body mass index (kg/m2,
mean  SD)
27.4  3 25.5  3
Total proteins (g/dL, mean  SD) 7.37  0.5 7.3  0.3
Creatinine clearance (mL/min,
mean  SD)
67  12 75  16
EuroSCORE
Median 3.5 4.0
Range 2–6 3–7
Type of surgery (no.)
CABG 5 5
Valve replacement 3 2
CABG and valve replacement 2 3
Duration of surgery (h, mean  SD) 4.3  0.6 4.7  0.7
Duration of cardiopulmonary bypass
(min, mean  SD)
48.6  9.2 47.2  13
All differences are nonsignificant. CABG, Coronary artery bypass grafting.
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Mrisk of sternal SSIs when only 1 g is administered.16 Neither
1 g cefazolin given before surgery nor a second dose of 1 g
just after initiation of CPB can guarantee optimum cefazolin
serum levels for prophylaxis.17 Although cefazolin is a time-
dependent molecule, this problem might be overcome by
administering higher doses, since faster bacterial killing is
observed when plasma levels are high because the drug
can bind simultaneously to multiple penicillin-binding pro-
teins.18 Intermittent high doses, such as 4 g before skin inci-
sion and 2 g at skin closure, although ensuring higher mean
peak plasma total concentrations, do not, however, prevent
significant interindividual variability, with trough levels be-
low the optimal pharmacokinetic and pharmacodynamic tar-
get in the interstitial fluid.19 The mean total concentrations
varied little and were always greater than 50 mg/L in our con-
tinuous infusion group. Our data agree with those of Waltrip
and coworkers,20 who studied wound concentrations of cefa-
zolin and found that continuous infusion guaranteed higher
serum levels, although our data were obtained with the
same total dose of drug in both groups. Moreover, Waltrip
and coworkers20 did not assay drug concentrations in myo-
cardial tissue, whereas in our study we showed that mainte-
nance of high and stable serum levels was confirmed when
higher tissue concentrations were compared.
The duration of prophylaxis in cardiac surgery is contro-
versial. Short-term prophylaxis for clean surgery should
cover bacteria at the time of skin incision while minimizing
antibiotic use to reduce costs and resistance. On the other
hand, longer-term prophylaxis can guarantee antimicrobial
coverage during the procedure and in the immediate after-
math, when there is risk of replication of contaminating
pathogens.21 Nonetheless, it has been found that prolonging
prophylaxis for longer than 48 hours does not reduce the in-
cidence of SSIs in cardiac surgery but does increase the
spread of resistance.22 We found that continuous infusion
provided higher plasma levels than intermittent administra-
tion for the first 24 hours without increasing the total amount
of drug given.
This study has some limitations. (1) The small number of
patients did not provide the power to assess differences inrdiovascular Surgery c Volume 140, Number 2 473
FIGURE 2. Free concentrations of cefazolin in serum. A, Intermittent group. B, Continuous infusion group. MIC, Minimal inhibitory concentration; CLSI,
Clinical Laboratory Standards Institute.
TABLE 2. Total and free trough serum cefazolin concentrations after intermittent or continuous administration of 5 g cefazolin
Total concentration Calculated mean free concentration
Time (h) Intermittent Continuous Intermittent Continuous
2.5
Mean  SD 44.6  11.1 57.5  12.9 8.9  2.3 11.5  2.6
Range 29–60.5 40.5–79.5 5.8–12.1 8.1–15.9
8.5
Mean  SD 37.80  17.8 53.6  11.3 7.56  3.56 10.72  2.27
Range 10.5–65.15 37–75 2.1–13.03 7.4–15
14.5
Mean  SD 34.1  19.2 51.3  18.1* 6.8  3.8 10.3  3.6*
Range 5.2–67.5 27.5–83 1.04–13.5 5.5–16.6
24
Mean  SD 14.9  10.3 52.5  19.4y 3.7  1.5 10.51  3.9y
Range 0–32 31.5–85 0–6.4 6.3–17
Calculation of mean free serum concentration assumes 80% bound to plasma proteins. Values of 0 represent concentrations below limit of detection (<0.125 mg/L). *P< .05 by
t test. yP< .01 by t test.
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IG free
     *
CG free
n= 3
n= 9
n= 7
n= 1
T> MIC8mg/l  90%
* p< 0.05 
FIGURE 3. Numbers of patients meeting pharmacokinetic and pharmaco-
dynamic target (time>90% of dosing interval when free concentration was
greater than minimal inhibitory concentration of 8 mg/L, T> MIC8mg/l
90%) in intermittent group (IG) and continuous infusion group (CG). Aster-
isk indicates P< .05.
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Mthe occurrence of SSIs, even though the groups were well
matched, surgery was performed by the same skilled operator,
and surgical time was standardized. On the other hand, this
was mainly a pharmacokinetic and pharmacodynamic study,
and the differences in pharmacokinetics and pharmacody-
namics that emerged between the administration modalities
are noteworthy. (2) We gave the same dose of cefazolin re-
gardless of the patient’s body weight. Patients’ mean body
mass index values were, however, similar between groups.
(3) Cefazolin serum levels were measured with a microbio-
logic method, which is less specific than high-performance
liquid chromatography. Intragroup variability, however,
was low (1.5%–6.8%). (4) The selection of 8 mg/L as the tar-
get threshold concentration of free serum cefazolin was some-
what arbitrary. It does, however, correspond to the 90%MIC
for S aureus and the MIC for E coli.
Despite these limitations, our data confirm that giving ce-
fazolin as a bolus followed by continuous infusion in cardiac
patients undergoing CPB achieves targeted pharmacokinetic
and pharmacodynamic parameters and better myocardial
tissue penetration in more patients without increased cost
or higher total dose. Although this study did not show a re-
duced number of SSIs, optimization the pharmacokinetic
and pharmacodynamic profile of an ‘‘old’’ but still useful
drug, without any additional cost, does appear to be an
appealing strategy to preserve its efficacy.The Journal of Thoracic and Ca
PWe thank Mary Forrest for editing the manuscript.
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